Patisiran (ALN-TTR02)

Jul 04, 2018
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Background: Patisiran, an investigational RNA interference therapeutic agent, specifically inhibits hepatic synthesis of transthyretin. Methods: In this phase 3…
Read more
alnylam_logo.png
FDA Approves Alnylam’s Onpattro for Polyneuropathy of hATTR Amyloidosis
The FDA today granted Alnylam Pharmaceuticals approval for a first-in-class small interfering ribonucleic acid (siRNA) treatment-the first therapy indicated for…
Read more
Subscribe to